Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma

ConclusionsOur results indicate that the development of AEs to bevacizumab or bevacizumab-containing regimens is associated with unfavorable glioma-related survival outcomes in patients with rGB.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research